OBIO
Orchestra BioMed Holdings, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.59
P/S
7.46
EV/EBITDA
-4.83
DCF Value
$-0.01
FCF Yield
-19.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-154.7%
Net Margin
-157.4%
ROE
-169.6%
ROA
-45.9%
ROIC
-52.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $30.9M | $6.2M | $0.11 |
| FY 2025 | $33.5M | $-53.0M | $-1.11 |
| Q3 2025 | $861.0K | $-20.8M | $-0.40 |
| Q2 2025 | $836.0K | $-19.4M | $-0.50 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.60
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.